Lenalidomide enhances antibody-dependent cellular cytotoxicity of solid tumor cells in vitro: Influence of host immune and tumor markers

Cancer Immunology, Immunotherapy

Volumn 60, Issue 1, 2011, Pages 61-73

  Wu, Lei ^a   Parton, Anastasia ^a   Lu, Ling ^a   Adams, Mary ^a   Schafer, Peter ^a   Bartlett, J Blake ^a  

^a CELGENE CORPORATION   (United States)

Author keywords

Antibody dependent cell mediated cytotoxicity; Fc R; Lenalidomide; Monoclonal antibodies; NK cell

Indexed keywords

B RAF KINASE; CD16 ANTIGEN; CETUXIMAB; DNAX ACCESSORY MOLECULE 1; EPIDERMAL GROWTH FACTOR RECEPTOR; K RAS PROTEIN; LENALIDOMIDE; NATURAL KILLER CELL ACTIVATING RECEPTOR; NATURAL KILLER CELL RECEPTOR; NATURAL KILLER CELL RECEPTOR NKG2D; TRASTUZUMAB; UNCLASSIFIED DRUG;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIGEN EXPRESSION; ARTICLE; BREAST CANCER; CANCER CELL; CANCER CELL CULTURE; COLON CANCER; CONTROLLED STUDY; DRUG MECHANISM; HEAD AND NECK CANCER; HUMAN; HUMAN CELL; IN VITRO STUDY; LUNG CANCER; NATURAL KILLER CELL; OSTEOSARCOMA; OVARY CANCER; PRIORITY JOURNAL; SOLID TUMOR;

ANTIBODIES, BLOCKING; ANTIBODIES, MONOCLONAL; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; ANTIGENS, DIFFERENTIATION, T-LYMPHOCYTE; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL LINE, TUMOR; CYTOTOXICITY, IMMUNOLOGIC; GPI-LINKED PROTEINS; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; KILLER CELLS, NATURAL; NEOPLASMS; NK CELL LECTIN-LIKE RECEPTOR SUBFAMILY K; RECEPTORS, VIRUS; SARCOMA; THALIDOMIDE; TUMOR MARKERS, BIOLOGICAL;

EID: 79953744107     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-010-0919-9     Document Type: Article

References (39)

1. Fowler NH, McLaughlin P, Kwak L, Hagemeister F, Fanale M, Fayad L, Pro B, Samaniego F (2009) Lenalidomide and rituximab for untreated indolent non-Hodgkin's lymphoma [abstract]. J Clin Oncol 27(15s):8548
2. Veliz M, Santana R, Lancet JE, Komrokji RS, Kharfan-Dabaja MA, Powers JJ, Dubovsky JA, Tinsley S, Deaver D, Sotomayor EM, Pinilla-Ibarz J (2009) Phase II study of lenalidomide in combination with rituximab for patients with CD5+/CD20+ hematologic malignancies who relapse or progress after rituximab. interim analysis [abstract]. Blood 114:2376
3. Ahmadi T, Chong EA, Gordon A, Aqui NA, Downs LH, Leinbach L, Goldstein SC, Nasta SD, Janofsky S, Maniar TN, Svoboda J, Schuster SJ (2009) Phase II trial of lenalidomide-dexamethasone-rituximab in relapsed or refractory indolent B-cell or mantle cell lymphomas resistant to rituximab [abstract]. Blood 114:1700
4. Kalmadi S, Davis M, Dowlati A, O'Keefe S, Cline-Burkhardt M, Pelley RJ, Borden E, Dreicer R, Bukowski R, Mekhail T (2007) Phase I trial of three-weekly docetaxel, carboplatin and oral lenalidomide (Revlimid) in patients with advanced solid tumors. Invest New Drugs 25:211-216. doi:10.1007/s10637-006-9025- 4 (Pubitemid 46774699)
5. Petrylak DP, Resto-Garces K, Tibyan M, Mohile SG (2009) A phase I open-label study using lenalidomide and docetaxel in castration- resistant prostate cancer [abstract]. J Clin Oncol 27(15s):5156
6. Sanborn SL, Gibbons J, Krishnamurthi S, Brell JM, Dowlati A, Bokar JA, Nock C, Horvath N, Bako J, Remick SC, Cooney MM (2009) Phase I trial of docetaxel given every 3 weeks and daily lenalidomide in patients with advanced solid tumors. Invest New Drugs 27:453-460. doi:10.1007/s10637-008-9200-x
7. Choueiri TK, Dreicer R, Rini BI, Elson P, Garcia JA, Thakkar SG, Baz RC, Mekhail TM, Jinks HA, Bukowski RM (2006) Phase II study of lenalidomide in patients with metastatic renal cell carcinoma. Cancer 107:2609-2616. doi:10.1002/cncr.22290 (Pubitemid 44845615)
8. Liu WM, Henry JY, Meyer B, Bartlett JB, Dalgleish AG, Galustian C (2009) Inhibition of metastatic potential in colorectal carcinoma in vivo and in vitro using immunomodulatory drugs (IMiDs). Br J Cancer 101:803-812. doi:10.1038/sj.bjc.6605206
9. Lu L, Payvandi F, Wu L, Zhang LH, Hariri RJ, Man HW, Chen RS, Muller GW, Hughes CC, Stirling DI, Schafer PH, Bartlett JB (2009) The anti-cancer drug lenalidomide inhibits angiogenesis and metastasis via multiple inhibitory eVects on endothelial cell function in normoxic and hypoxic conditions. Microvasc Res 77:78-86. doi:10.1016/j.mvr.2008.08.003
10. Haslett PA, Hanekom WA, Muller G, Kaplan G (2003) Thalidomide and a thalidomide analogue drug costimulate virus-specific CD8+ T cells in vitro. J Infect Dis 187:946-955. doi:10.1086/368126 (Pubitemid 36337907)
11. Corral LG, Haslett PA, Muller GW, Chen R, Wong LM, Ocampo CJ, Patterson RT, Stirling DI, Kaplan G (1999) DiVerential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha. J Immunol 163:380-386 (Pubitemid 29295864)
12. Marriott JB, Clarke IA, Dredge K, Muller G, Stirling D, Dalgleish AG (2002) Thalidomide and its analogues have distinct and opposing eVects on TNF-alpha and TNFR2 during co-stimulation of both CD4(+) and CD8(+) T cells. Clin Exp Immunol 130:75-84. doi:10.1046/j.1365-2249.2002.01954.x
13. Hayashi T, Hideshima T, Akiyama M, Podar K, Yasui H, Raje N, Kumar S, Chauhan D, Treon SP, Richardson P, Anderson KC (2005) Molecular mechanisms whereby immunomodulatory drugs activate natural killer cells: clinical application. Br J Haematol 128:192-203. doi:10.1111/j.1365-2141.2004.05286.x
14. Davies FE, Raje N, Hideshima T, Lentzsch S, Young G, Tai YT, Lin B, Podar K, Gupta D, Chauhan D, Treon SP, Richardson PG, Schlossman RL, Morgan GJ, Muller GW, Stirling DI, Anderson KC (2001) Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood 98:210-216
15. LeBlanc R, Hideshima T, Catley LP, Shringarpure R, Burger R, Mitsiades N, Mitsiades C, Cheema P, Chauhan D, Richardson PG, Anderson KC, Munshi NC (2004) Immunomodulatory drug costimulates T cells via the B7-CD28 pathway. Blood 103:1787-1790. doi:10.1182/blood-2003-02-0361 (Pubitemid 38268973)
16. Chang DH, Liu N, Klimek V, Hassoun H, Mazumder A, Nimer SD, Jagannath S, Dhodapkar MV (2006) Enhancement of ligand-dependent activation of human natural killer T cells by lenalidomide: therapeutic implications. Blood 108:618-621. doi:10.1182/blood-2005-10-4184 (Pubitemid 44061362)
17. Hernandez-Ilizaliturri FJ, Reddy N, Holkova B, Ottman E, Czuczman MS (2005) Immunomodulatory drug CC-5013 or CC-4047 and rituximab enhance antitumor activity in a severe combined immunodeWcient mouse lymphoma model. Clin Cancer Res 11:5984-5992. doi:10.1158/1078-0432.CCR-05-0577 (Pubitemid 41170330)
18. Wu L, Adams M, Carter T, Chen R, Muller G, Stirling D, Schafer P, Bartlett JB (2008) Lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20+ tumor cells. Clin Cancer Res 14:4650-4657. doi:10.1158/1078-0432.CCR-07- 4405
19. Lapalombella R, Gowda A, Joshi T, Mehter N, Cheney C, Lehman A, Chen CS, Johnson AJ, Caligiuri MA, Tridandapani S, Muthusamy N, Byrd JC (2009) The humanized CD40 antibody SGN-40 demonstrates pre-clinical activity that is enhanced by lenalidomide in chronic lymphocytic leukaemia. Br J Haematol 144:848-855. doi:10.1111/j.1365-2141.2008.07548.x
20. Tai YT, Li XF, Catley L, CoVey R, Breitkreutz I, Bae J, Song W, Podar K, Hideshima T, Chauhan D, Schlossman R, Richardson P, Treon SP, Grewal IS, Munshi NC, Anderson KC (2005) Immunomodulatory drug lenalidomide (CC-5013, IMiD3) augments anti-CD40 SGN-40-induced cytotoxicity in human multiple myeloma: clinical implications. Cancer Res 65:11712-11720. doi:10.1158/0008-5472.CAN-05- 1657 (Pubitemid 41821732)
21. Awan FT, Lapalombella R, Trotta R, Butchar JP, Yu B, Benson DM Jr, Roda JM, Cheney C, Mo X, Lehman A, Jones J, Flynn J, Jarjoura D, Desjarlais JR, Tridandapani S, Caligiuri MA, Muthusamy N, Byrd JC (2010) CD19 targeting of chronic lymphocytic leukemia with a novel Fc-domain engineered monoclonal antibody. Blood 115:1204-1213. doi:10.1182/blood-2009-06-229039
22. Reddy N, Hernandez-Ilizaliturri FJ, Deeb G, Roth M, Vaughn M, Knight J, Wallace P, Czuczman MS (2008) Immunomodulatory drugs stimulate natural killer-cell function, alter cytokine production by dendritic cells, and inhibit angiogenesis enhancing the antitumour activity of rituximab in vivo. Br J Haematol 140:36-45. doi:10.1111/j.1365-2141.2007.06841.x (Pubitemid 350233246)
23. Zhu D, Corral LG, Fleming YW, Stein B (2008) Immunomodulatory drugs revlimid (lenalidomide) and CC-4047 induce apoptosis of both hematological and solid tumor cells through NK cell activation. Cancer Immunol Immunother 57:1849-1859. doi:10.1007/s00262-008-0512-7
24. Xu Y, Wu H, Sun J, Seeger RC (2009) Activation of antitumor functions of natural killer cells and suppression of pro-tumor functions of monocytes by lenalidomide [abstract]. J Immunother 32:965
25. Bartlett JB, Michael A, Clarke IA, Dredge K, Nicholson S, Kristeleit H, Polychronis A, Pandha H, Muller GW, Stirling DI, Zeldis J, Dalgleish AG (2004) Phase I study to determine the safety, tolerability and immunostimulatory activity of thalidomide analogue CC-5013 in patients with metastatic malignant melanoma and other advanced cancers. Br J Cancer 90:955-961. doi:10.1038/sj.bjc.6601579 (Pubitemid 38495811)
26. Ayello J, Berg SL, Krailo M, van de Ven C, Ingle AM, Lewis D, Harrison L, Blaney S, Adamson PC, Cairo MS (2008) Lenalidomide (LMID) signiWcantly enhances circulating serum levels of IL-2 and IL-15 levels, NK expansion and activation and NK and LAK cytotoxicity in children with refractory/recurrent solid tumors: a children's oncology phase I consortium report [abstract]. Blood 112:107
27. Zamai L, Ponti C, Mirandola P, Gobbi G, Papa S, Galeotti L, Cocco L, Vitale M (2007) NK cells and cancer. J Immunol 178:4011-4016 (Pubitemid 46492347)
28. El-Sherbiny YM, Meade JL, Holmes TD, McGonagle D, Mackie SL, Morgan AW, Cook G, Feyler S, Richards SJ, Davies FE, Morgan GJ, Cook GP (2007) The requirement for DNAM-1, NKG2D, and NKp46 in the natural killer cell-mediated killing of myeloma cells. Cancer Res 67:8444-8449. doi:10.1158/0008-5472.CAN-06- 4230
29. Li K, Mandai M, Hamanishi J, Matsumura N, Suzuki A, Yagi H, Yamaguchi K, Baba T, Fujii S, Konishi I (2009) Clinical signiWcance of the NKG2D ligands, MICA/B and ULBP2 in ovarian cancer: high expression of ULBP2 is an indicator of poor prognosis. Cancer Immunol Immunother 58:641-652. doi:10.1007/s00262-008- 0585-3
30. Groh V, Wu J, Yee C, Spies T (2002) Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation. Nature 419:734-738. doi:10.1038/nature01112 (Pubitemid 35177960)
31. Jinushi M, Vanneman M, Munshi NC, Tai YT, Prabhala RH, Ritz J, Neuberg D, Anderson KC, Carrasco DR, DranoV G (2008) MHC class I chain-related protein A antibodies and shedding are associated with the progression of multiple myeloma. Proc Natl Acad Sci USA 105:1285-1290. doi:10.1073/pnas.0711293105 (Pubitemid 351397045)
32. Pende D, Spaggiari GM, Marcenaro S, Martini S, Rivera P, Capobianco A, Falco M, Lanino E, Pierri I, Zambello R, Bacigalupo A, Mingari MC, Moretta A, Moretta L (2005) Analysis of the receptor-ligand interactions in the natural killer-mediated lysis of freshly isolated myeloid or lymphoblastic leukemias: evidence for the involvement of the Poliovirus receptor (CD155) and Nectin-2 (CD112). Blood 105:2066-2073. doi:10.1182/blood-2004-09-3548 (Pubitemid 40731793)
33. Castriconi R, Dondero A, Corrias MV, Lanino E, Pende D, Moretta L, Bottino C, Moretta A (2004) Natural killer cell-mediated killing of freshly isolated neuroblastoma cells: critical role of DNAX accessory molecule-1-poliovirus receptor interaction. Cancer Res 64:9180-9184. doi:10.1158/0008-5472.CAN-04-2682 (Pubitemid 39665534)
34. Ravetch JV, Perussia B (1989) Alternative membrane forms of Fc gamma RIII(CD16) on human natural killer cells and neutrophils. Cell type-specific expression of two genes that diVer in single nucleotide substitutions. J Exp Med 170:481-497 (Pubitemid 19204276)
35. Diermayr S, Himmelreich H, Durovic B, Mathys-Schneeberger A, Siegler U, Langenkamp U, Hofsteenge J, Gratwohl A, Tichelli A, Paluszewska M, Wiktor-Jedrzejczak W, Kalberer CP, Wodnar-Filipowicz A (2008) NKG2D ligand expression in AML increases in response to HDAC inhibitor valproic acid and contributes to allorecognition by NK-cell lines with single KIR-HLA class I specificities. Blood 111:1428-1436. doi:10.1182/blood-2007-07-101311 (Pubitemid 351213430)
36. Schneider-Merck T, Lammerts van Bueren JJ, Berger S, Rossen K, van Berkel PH, Derer S, Beyer T, Lohse S, Bleeker WK, Peipp M, Parren PW, van de Winkel JG, Valerius T, Dechant M (2010) Human IgG2 antibodies against epidermal growth factor receptor eVectively trigger antibody-dependent cellular cytotoxicity but, in contrast to IgG1, only by cells of myeloid lineage. J Immunol 184:512-520. doi:10.4049/jimmunol.0900847
37. López-Albaitero A, Lee SC, Morgan S, Grandis JR, Gooding WE, Ferrone S, Ferris RL (2009) Role of polymorphic Fc gamma receptor IIIa and EGFR expression level in cetuximab mediated, NK cell dependent in vitro cytotoxicity of head and neck squamous cell carcinoma cells. Cancer Immunol Immunother 58:1853-1864. doi:10.1007/s00262-009-0697-4
38. Lapalombella R, Yu B, TriantaWllou G, Liu Q, Butchar JP, Lozanski G, Ramanunni A, Smith LL, Blum W, Andritsos L, Wang DS, Lehman A, Chen CS, Johnson AJ, Marcucci G, Lee RJ, Lee LJ, Tridandapani S, Muthusamy N, Byrd JC (2008) Lenalidomide down-regulates the CD20 antigen and antagonizes direct and antibody-dependent cellular cytotoxicity of rituximab on primary chronic lymphocytic leukemia cells. Blood 112:5180-5189. doi:10.1182/blood-2008-01- 133108
39. Hatjiharissi E, Xu L, Santos DD, Hunter ZR, Ciccarelli BT, Verselis S, Modica M, Cao Y, Manning RJ, Leleu X, Dimmock EA, Kortsaris A, Mitsiades C, Anderson KC, Fox EA, Treon SP (2007) Increased natural killer cell expression of CD16, augmented binding and ADCC activity to rituximab among individuals expressing the Fc{gamma}RIIIa-158 V/V and V/F polymorphism. Blood 110:2561-2564. doi:10.1182/blood-2007-01-070656 (Pubitemid 47523179)